WiSys Technologies

13 WiSys Technologies in "Pharmaceuticals & Vitamin D" or "Diagnostic Assays" or "Micro & Nanotech"

Non-Linear Stimuli-Responsive Block Copolymers as Dispersants and Rheological Modifiers in Architectural Coatings

WiSys is currently seeking strategic partners in the coatings industry that are interested in co-development opportunities that would ultimately provide a route to market for commercialization of these novel copolymers.

Linear Stimuli-Responsive Block Copolymers as Dispersants and Rheological Modifiers in Architectural Coatings

WiSys is currently seeking strategic partners in the coatings industry that are interested in co-development opportunities that would ultimately provide a route to market for commercialization of these novel copolymers. 

Carbon Nanotube Vacuum Field Emission Transistor Design for Large-Scale Manufacturing

WiSys is currently seeking strategic partners in the next generation transistor industry that are interested in further optimizing the design for large-scale manufacturing, ultimately providing a path to market for its commercialization.

Porous Silicon Nanomembranes for the Rapid Separation of Macromolecules by Size and Shape

WiSys is seeking a strategic partner skilled in the development and manufacturing of membranes used for the separation and/or detection of biologic molecules in solution.  There is additional interest in a partner with the expertise to identify and test novel applications for these nanomembranes.

Skin Whitening Agent(s)

WiSys Technology Foundation is currently seeking a strategic industry partner to assist in the further development of its lead compound, A11, and related analogues providing a route to market for their use as novel skin whitening/lightening agents.The competitive advantage of these compounds over existing agents on the market is that they produce long-acting and reversible skin lightening with no toxicity.

Benzodiazepine Derivatives with Reduced Side Effects

The WiSys Technology Foundation is seeking commercial partners interested in developing anxiolytic and anticonvulsant benzodiazepines that offer little or no side effects.